Intuitive Surgical (ISRG)
NASDAQ:ISRG
ISRG Stock Chart & Stats
$452.66
$11.55(2.17%)
At close: 4:00 PM EST
$452.66
$11.55(2.17%)
Day’s Range― - ―
52-Week Range$425.00 - $603.88
Previous CloseN/A
Volume485.62K
Average Volume (3M)1.58M
Market Cap
$160.75B
Enterprise Value$157.69B
Total Cash (Recent Filing)$5.93B
Total Debt (Recent Filing)$302.80M
Price to Earnings (P/E)70.8
Beta1.17
Next Earnings
Apr 21, 2026EPS Estimate
2.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.53
Shares Outstanding355,130,250
10 Day Avg. Volume1,567,265
30 Day Avg. Volume1,579,489
Financial Highlights & Ratios
PEG Ratio3.17
Price to Book (P/B)11.34
Price to Sales (P/S)20.08
P/FCF Ratio81.16
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue15.67
Enterprise Value/Gross Profit23.74
Enterprise Value/Ebitda43.53
Forecast
1Y Price Target
$634.40Price Target Upside40.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)10.05
Revenue Forecast (FY)$11.52B
Bulls Say, Bears Say
Bulls Say
Acquisition And Technology IntegrationAcquisition of a company developing integrated robotics and AI tissue‑assessment technology strengthens the surgical robotics portfolio and could enable faster, image‑guided biopsy workflows across lung, liver, pancreas, breast and lymph nodes.
Advanced Imaging InnovationDye‑free, real‑time tissue oxygenation imaging produces quantitative oxygenation maps without contrast agents, simplifying workflow and potentially improving surgical decision making and outcomes.
Next‑generation Platform AdoptionEarly global rollout of the DV5 surgical platform is expected to prompt hospital fleet upgrades, placement of refurbished systems in price‑sensitive sites, and broader procedure volumes across general and cardiac surgery.
Bears Say
Procedure Adoption RiskComplexity of cardiac procedures suggests robotic adoption will be gradual, limiting near‑term market penetration and tempering revenue growth from advanced cardiac indications.
Product Safety And ReputationReports of serious adverse events tied to affected reloads and customer advisories to stop using them raise safety and reputational concerns that could reduce surgeon confidence and hospital purchases.
Regulatory ScrutinyAn FDA alert advising customers not to use the affected reloads signals elevated regulatory scrutiny that could lead to additional restrictions, recalls, or higher compliance costs.
Intuitive Surgical News
ISRG FAQ
What was Intuitive Surgical’s price range in the past 12 months?
Intuitive Surgical lowest stock price was $425.00 and its highest was $603.88 in the past 12 months.
What is Intuitive Surgical’s market cap?
Intuitive Surgical’s market cap is $160.75B.
When is Intuitive Surgical’s upcoming earnings report date?
Intuitive Surgical’s upcoming earnings report date is Apr 21, 2026 which is in 23 days.
How were Intuitive Surgical’s earnings last quarter?
Intuitive Surgical released its earnings results on Oct 18, 2018. The company reported $0.943 earnings per share for the quarter, beating the consensus estimate of N/A by $0.943.
Is Intuitive Surgical overvalued?
According to Wall Street analysts Intuitive Surgical’s price is currently Undervalued.
Does Intuitive Surgical pay dividends?
Intuitive Surgical does not currently pay dividends.
What is Intuitive Surgical’s EPS estimate?
Intuitive Surgical’s EPS estimate is 2.13.
How many shares outstanding does Intuitive Surgical have?
Intuitive Surgical has 355,130,250 shares outstanding.
What happened to Intuitive Surgical’s price movement after its last earnings report?
Intuitive Surgical reported an EPS of $0.943 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.346%.
Which hedge fund is a major shareholder of Intuitive Surgical?
Currently, no hedge funds are holding shares in ISRG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Intuitive Surgical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$634.40 (40.15% Upside)
$634.40 (40.15% Upside)
Blogger Sentiment
Bullish
ISRG Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 38.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bullish
Bullish news 95%
Bearish news 5%
Bearish news 5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.87%
12-Months-Change
Fundamentals
Return on Equity
16.39%
Trailing 12-Months
Asset Growth
9.52%
Trailing 12-Months
Company Description
Intuitive Surgical
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
ISRG Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call described strong top-line and procedure growth, meaningful increases in cash flow and profitability, rapid adoption of new platforms (da Vinci 5, SP, Ion), and continued product and clinical progress. Offsetting these positives are margin pressures from tariffs and product mix, elevated operating expenses (including a large foundation donation and hiring), competitive pricing/tender dynamics in China, placement softness in Japan, and lower Ion placements in Q4. On balance the company reported multiple high-growth metrics and solid cash generation while outlining manageable but notable near-term headwinds.View all ISRG earnings summariesISRG Revenue Breakdown
67.72% U.S.
32.28% Outside of U.S
ISRG Stock 12 Month Forecast
Average Price Target
$634.40
▲(40.15% Upside)
Technical Analysis
Baxter International
―
Becton Dickinson
―
Hologic
―
Resmed
―
West Pharmaceutical Services
―
Ownership Overview
0.47% Insiders
22.15% Mutual Funds
21.23% Other Institutional Investors
30.90% Public Companies and Individual Investors